Aquestive Therapeutics (AQST) Key Ratios
$5.35
As on 03-Sep-2026 16:26EDT
Market cap
$630 Mln
Revenue (TTM)
$54 Mln
P/E Ratio
--
P/B Ratio
14.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -4.34 | 38.15 | 22.56 | 5.15 | 5.25 |
| EBIT | -361.64 | -105.18 | -28.75 | -234.17 | -9.84 |
| Net Profit | -183.78 | -68.76 | -20.27 | -213.43 | -4.92 |
| EPS | -178.37 | -34.11 | 5.85 | -17.21 | 10.50 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -65.84 | -76.02 | -114.45 | -149.70 | -47.49 |
| Net Margin
| -- | -188.44 | -144.63 | -- | -- |
| Return on equity
| 79.53 | 80.16 | -- | 178.61 | 52.97 |
| Return on Capital
| -39.08 | 85.28 | -- | -221.56 | 92.61 |
| Return on Assets
| -44.44 | -67.54 | -42.58 | -63.99 | -55.57 |
| Debt to Equity (x)
| -- | -- | 0.00 | -3.90 | -0.63 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
-221.56
|
92.61
|
11.73
|
125.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
178.61
|
52.97
|
6.99
|
54.22
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-42.58
Lower than Peers by 45.44
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-42.58
|
-63.99
|
-55.57
|
-13.75
|
-91.40
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
-114.45
Lower than Peers by 130.27
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-114.45
|
-149.70
|
-47.49
|
-0.32
|
-88.02
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
-144.63
Lower than Peers by 152.86
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-144.63
|
-188.09
|
-76.68
|
-15.56
|
-114.11
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
22.56
Higher than Peers by 14.51
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
22.56
|
-0.23
|
0.14
|
0.06
|
-0.06
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
-28.75
Lower than Peers by 37.02
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-28.75
|
-143.96
|
-16,669.33
|
99.61
|
12.71
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
-20.27
Lower than Peers by 28.00
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-20.27
|
-89.83
|
-460.83
|
85.54
|
22.87
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
5.85
Lower than Peers by 4.55
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
5.85
|
-0.42
|
-3.21
|
0.89
|
0.43
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
38.05
Higher than Peers by 33.18
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
38.05
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
-3.90
|
-0.63
|
-0.31
|
-0.48
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-0.01
|
-0.35
|
-0.01
|
0.00
|
-0.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
7.19
Higher than Peers by 5.54
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
7.19
|
3.14
|
4.68
|
2.24
|
1.01
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
6.74
Higher than Peers by 5.54
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
6.74
|
3.01
|
4.36
|
1.87
|
0.86
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
-3.79
Lower than Peers by 8.56
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-3.79
|
-3.90
|
-1.63
|
-0.02
|
-3.37
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
17.24
Lower than Peers by 4.03
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
17.24
|
39.88
|
12.76
|
16.75
|
9.87
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.29
Lower than Peers by 0.10
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
0.29
|
0.34
|
0.72
|
0.88
|
0.80
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
102.93
|
50.18
|
47.57
|
64.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
130.02
|
130.93
|
110.02
|
92.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
427.43
|
196.33
|
165.45
|
172.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
-194.47
|
-15.22
|
-7.87
|
-15.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
-9.40
|
-7.36
|
-17.59
|
-0.90
|
|
Peer Median
|
37.32
|
--
|
--
|
--
|
--
|
Price / Book Value
14.15
Higher than Peers by 6.39
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
14.15
|
-23.41
|
-5.40
|
-1.30
|
-0.41
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.81
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
-1.81
|
-12.07
|
-10.94
|
125.11
|
-2.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
630
Lower than Peers by 1,891
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
|
630
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|